Roth Capital Initiates Guardant Health (GH) at Buy

Roth Capital initiated coverage on Guardant Health, Inc. (NasdaqGS: GH) on October 23, 2026, giving the precision oncology firm a Buy rating and a $200.0 price target. According to a research note released on the same day, the firm launched its outlook with a bullish stance on the stock. Guardant Health closed at $162.94 on October 22, 2026.

GH Guardant Health, Inc.

$162.94 ▲ +60.15% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Other Institutional Activity in Guardant Health

Other large funds have adjusted their stakes in the diagnostics company recently. Two Sigma Investments, LP reduced its holdings by 510,061 shares, ending with 3,719,301 shares worth about $606,022,914. Capital International Investors trimmed its position by 81,813 shares, leaving it with 3,399,604 shares valued at roughly $553,931,484. Deep Track Capital, Lp grew its holdings by 55,081 shares, ending with 3,393,312 shares worth about $552,906,265.

Guardant Health, Inc. Stock Down 2.2%

Guardant Health shares recently traded around $162.94 as of October 23, 2026, sitting about 2.9% below their 50-day moving average of $167.87 and 27.8% above their 200-day moving average of $127.54. The stock trades 14.7% below its 52-week high of $191.05 and well above its 52-week low of $66.59.

Recent Earnings

Guardant Health reported trailing-twelve-month revenue of $1.18 billion alongside a year-over-year revenue growth rate of 44.3%. The company posted a net profit margin of -38.3% and basic earnings per share of -3.5 over the same period. The firm is not currently profitable on a trailing basis, resulting in no meaningful trailing P/E ratio. Investors will look toward the company's upcoming earnings release on November 5, 2026, for fresh financial details.

Insider Buying and Selling at Guardant Health, Inc.

Company insiders have been active in the market over recent months. Co-Chief Executive Officer Amirali Talasaz executed transactions on June 26 and June 29, 2026. Director Alex M Azar II sold 69 shares on October 14, 2026, at an average price of $159.89 under a planned arrangement, totaling about $11,032.41.

Analysts Set New Price Targets

Wall Street firms continue to update their views on the stock. On September 9, 2026, UBS maintained its Buy rating while raising its price target to $225.0 from $175.0. Guggenheim maintained a Buy rating on October 1, 2026, lifting its target to $200.0 from $190.0. Barclays maintained an Overweight rating on October 7, 2026, adjusting its target to $220.0 from $200.0. Morgan Stanley maintained an Overweight rating on October 13, 2026, moving its target to $200.0 from $185.0. Overall, the stock carries a strong buy recommendation consensus across 25 analyst opinions, with a mean target price of $201.64.

About Guardant Health

Guardant Health, Inc. is a precision oncology company headquartered in Palo Alto, California. It develops blood and tissue tests along with data sets to help clinicians manage cancer treatment in the United States and internationally. Analysts and institutional investors watch its pipeline and test adoption rates closely as key drivers of future growth.

Bottom Line

Roth Capital's new coverage adds to a largely positive Wall Street sentiment ahead of the company's scheduled November earnings report. Market participants will monitor upcoming filings and volume trends to see how institutional appetite evolves.